The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)

ClinicalTrials.gov ID: NCT02269267

Public ClinicalTrials.gov record NCT02269267. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a non-randomized, prospective, single-group longitudinal study. The purpose of this study is to improve the decision making process used by physicians and patients when they are considering stopping their Tyrosine Kinase Inhibitor (TKI) medication.

Study identification

NCT ID: NCT02269267
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Medical College of Wisconsin; Other
Enrollment: 173 participants

Conditions and interventions

Conditions

Leukemia, Myeloid, Chronic

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 18, 2014 (Actual)
Primary completion: Apr 6, 2021 (Actual)
Completion: Apr 6, 2022 (Actual)
Last update posted: Mar 3, 2023

2014 – 2022

United States locations

U.S. sites: 16
U.S. states: 12
U.S. cities: 14

Facility	City	State	ZIP	Site status
Helen Diller Family Comprehensive Cancer Center University of California	San Francisco	California	94143	—
Moffit Cancer Center	Tampa	Florida	33612	—
Winship Cancer Institute of Emory University	Atlanta	Georgia	30322	—
The University of Chicago	Chicago	Illinois	60637	—
The University of Chicago Medicine Comprehensive Cancer Center at Silver Cross	New Lenox	Illinois	60451	—
Beth Israel Deaconess Medical Center (Satellite site of Dana Farber) Beth Israel Deaconess Medical Center	Boston	Massachusetts	02215	—
Dana Farber Cancer Institute	Boston	Massachusetts	02215	—
Karmanos Cancer Institute of Wayne State University	Detroit	Michigan	48201	—
Roswell Park Cancer Institute	Buffalo	New York	14263	—
Weill Medical College of Cornell University	New York	New York	10021	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
Duke University Medical Center	Durham	North Carolina	27710	—
MD Anderson Cancer Center	Houston	Texas	77054	—
University of Utah Huntsman Cancer Institute	Salt Lake City	Utah	84132-2408	—
Fred Hutchinson Cancer Research Center	Seattle	Washington	98109-1024	—
Froedtert Hospital & Medical College of Wisconsin	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02269267, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 3, 2023 · Synced Oct 24, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02269267 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →